In our study, we surprisingly identified immune index having significant differences between low-risk and medium- to high-risk MDS patients, and serum IL-4 showed great effects on the survival of MDS patients in different prognostic scoring systems. This evidence concerns the gene IL4 and myelodysplastic syndrome.